The complete official instructions for Enantuzumab

Elranatamab (Elranatamab), trade nameELREXFIO, is an innovative bispecific antibody therapy designed to treat adult patients with relapsed or refractory multiple myeloma (RRMM). The research and development of this drug focuses on targeting BCMA (B cell mature antigen) and CD3, using T cells to target malignant plasma cells. It is one of the promising new immunotherapy drugs in the field of hematological tumors in recent years. ELREXFIO has received conditional approval in Europe and the United States, and its targeting properties and clinical efficacy have attracted widespread attention from the medical community.

1. Indications:

Enatuzumab is mainly suitable for the treatment of adult multiple myeloma patients who have received at least four lines of therapy. These previous treatment regimens need to include proteasome inhibitors (such as bortezomib), immunomodulators (such as lenalidomide) andCD38-targeting monoclonal antibodies (such as daratumumab). For this type of highly drug-resistant patient group, traditional treatments often have limited efficacy, and the BCMA/CD3 dual-target mechanism of eractuzumab is expected to significantly improve the treatment response rate and prolong progression-free survival.

2. Usage and dosage analysis:

1. Initial dose escalation phase (preparation for the first round of treatment)

Day Day 1: Give 12mg subcutaneous injection, called the first incremental dose;

Day Day 4: Give 32mg subcutaneous injection as the second incremental dose;

Day Day 8: The standard therapeutic dose of 76 mg subcutaneous injection is officially started. This is the first dose of complete treatment.

The purpose of this gradually increasing dosing method is to control and prevent cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These two side effects are relatively common in bispecific antibody treatment. Therefore, it is recommended to be hospitalized for 48 hours after the first dose and 24 hours after the second dose.

2. Maintenance treatment stage (long-term efficacy consolidation)

Day Day 9 to Week 24: 76mg subcutaneous injection weekly;

Starting from week : If the treatment is effective, the patient can reduce the frequency of injections to once every two weeks, still 76 mg each time, and continue taking the drug until disease progression or intolerable toxicity occurs.

This two-stage treatment strategy not only ensures the sustainability of the drug effect, but also brings better compliance and quality of life protection to patients taking the drug for a long time.

3. Administration methods and special precautions:

Enantuzumab is only available for subcutaneous injection. Intravenous or intramuscular injection is prohibited to avoid adverse pharmacokinetic reactions and adverse events. Before each dose increase, glucocorticoids (such as dexamethasone), antihistamines (such as diphenhydramine) and antipyretics (such as acetaminophen) must be used in combination according to the instructions to effectively reduce the incidence of adverse immune reactions such as CRS.

4. Management after discontinuation of treatment:

If the patient interrupts treatment due to toxic reactions, he should not directly return to the original dose when restarting, but needs to follow the dose escalation strategy again, that is, gradually transition from 12mg→32mg→76mg. This method can effectively reduce the risk of immunity when taking medication again and ensure safety.

As a BCMA/CD3 bispecific T cell engagerenatuzumab has the characteristics of strong targeting, rapid efficacy, and controllable safety. It is currently one of the important treatment options for patients with relapsed or refractory multiple myeloma. The ascending dose design, subcutaneous injection route and CRS preventive measures in the instructions reflect the high degree of balance between safety and efficacy of modern targeted immunotherapy. With the continuous breakthroughs of immunotherapy in hematological malignancies, eractuzumab is expected to become an important part of the standard treatment plan for multiple myeloma in the future, especially suitable for patients with clear molecular characteristics and resistance to traditional therapies.

Reference materials:https://www.drugs.com/mtm/elranatamab.html